Literature DB >> 28063991

The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response.

Emad I Wafa1, Sean M Geary1, Jonathan T Goodman2, Balaji Narasimhan2, Aliasger K Salem3.   

Abstract

The goal of this research was to study the effect of polyanhydride chemistry on the immune response induced by a prophylactic cancer vaccine based on biodegradable polyanhydride particles. To achieve this goal, different compositions of polyanhydride copolymers based on 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), 1,6-bis-(p-carboxyphenoxy)-hexane (CPH), and sebacic anhydride (SA) were synthesized by melt polycondensation, and polyanhydride copolymer particles encapsulating a model antigen, ovalbumin (OVA), were then synthesized using a double emulsion solvent evaporation technique. The ability of three different compositions of polyanhydride copolymers (50:50 CPTEG:CPH, 20:80 CPTEG:CPH, and 20:80 CPH:SA) encapsulating OVA to elicit immune responses was investigated. In addition, the impact of unmethylated oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODN), an immunological adjuvant, on the immune response was also studied. The immune response to cancer vaccines was measured after treatment of C57BL/6J mice with two subcutaneous injections, seven days apart, of 50μg OVA encapsulated in particles composed of different polyanhydride copolymers with or without 25μg CpG ODN. In vivo studies showed that 20:80 CPTEG:CPH particles encapsulating OVA significantly stimulated the highest level of CD8+ T lymphocytes, generated the highest serum titers of OVA-specific IgG antibodies, and provided longer protection against tumor challenge with an OVA-expressing thymoma cell line in comparison to formulations made from other polyanhydride copolymers. The results also revealed that vaccination with CpG ODN along with polyanhydride particles encapsulating OVA did not enhance the immunogenicity of OVA. These results accentuate the crucial role of the copolymer composition of polyanhydrides in stimulating the immune response and provide important insights on rationally designing efficacious cancer vaccines. STATEMENT OF SIGNIFICANCE: Compared to soluble cancer vaccine formulations, tumor antigens encapsulated in biodegradable polymeric particles have been shown to sustain antigen release and provide long-term protection against tumor challenge by improving the immune response towards the antigen. Treatment of mice with cancer vaccines based on different polyanhydride copolymers encapsulating OVA resulted in stimulation of tumor-specific immune responses with different magnitudes. This clearly indicates that polyanhydride chemistry plays a substantial role in stimulating the immune response. Vaccination with 20:80 CPTEG:CPH/OVA, the most hydrophobic formulation, stimulated the strongest cellular and humoral immune responses and provided the longest survival outcome without adding any other adjuvant. The most important finding in this study is that the copolymer composition of polyanhydride particle-based vaccines can have a direct effect on the magnitude of the antitumor immune response and should be selected carefully in order to achieve optimal cancer vaccine efficacy.
Copyright © 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant; Antigen; Antitumor immune response; Biodegradable polymer; Cancer vaccine; Polyanhydrides

Mesh:

Substances:

Year:  2017        PMID: 28063991      PMCID: PMC5316298          DOI: 10.1016/j.actbio.2017.01.005

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  61 in total

1.  Carbohydrate-functionalized nanovaccines preserve HIV-1 antigen stability and activate antigen presenting cells.

Authors:  J E Vela Ramirez; R Roychoudhury; H H Habte; M W Cho; N L B Pohl; B Narasimhan
Journal:  J Biomater Sci Polym Ed       Date:  2014-07-28       Impact factor: 3.517

Review 2.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.

Authors:  Donald E Owens; Nicholas A Peppas
Journal:  Int J Pharm       Date:  2005-11-21       Impact factor: 5.875

3.  Criteria impacting the cellular uptake of nanoparticles: a study emphasizing polymer type and surfactant effects.

Authors:  A Musyanovych; J Dausend; M Dass; P Walther; V Mailänder; K Landfester
Journal:  Acta Biomater       Date:  2011-08-03       Impact factor: 8.947

4.  Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer.

Authors:  Enock Anassi; Uche Anadu Ndefo
Journal:  P T       Date:  2011-04

5.  Structural and antigenic stability of H5N1 hemagglutinin trimer upon release from polyanhydride nanoparticles.

Authors:  Kathleen A Ross; Hyelee Loyd; Wuwei Wu; Lucas Huntimer; Michael J Wannemuehler; Susan Carpenter; Balaji Narasimhan
Journal:  J Biomed Mater Res A       Date:  2014-02-04       Impact factor: 4.396

6.  Characterizing the antitumor response in mice treated with antigen-loaded polyanhydride microparticles.

Authors:  Vijaya B Joshi; Sean M Geary; Brenda R Carrillo-Conde; Balaji Narasimhan; Aliasger K Salem
Journal:  Acta Biomater       Date:  2012-11-12       Impact factor: 8.947

7.  Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.

Authors:  Samar Hamdy; Ommoleila Molavi; Zengshuan Ma; Azita Haddadi; Aws Alshamsan; Zahra Gobti; Sara Elhasi; John Samuel; Afsaneh Lavasanifar
Journal:  Vaccine       Date:  2008-08-03       Impact factor: 3.641

8.  A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4.

Authors:  Jay T Evans; Jon R Ward; Jeff Kern; Mark E Johnson
Journal:  Vaccine       Date:  2004-05-07       Impact factor: 3.641

9.  CpG oligodeoxynucleotides as immunotherapy in cancer.

Authors:  Bernd Jahrsdörfer; George J Weiner
Journal:  Update Cancer Ther       Date:  2008-03

10.  Polyanhydride Nanovaccines Induce Germinal Center B Cell Formation and Sustained Serum Antibody Responses.

Authors:  Julia E Vela Ramirez; Lorraine T Tygrett; Jihua Hao; Habtom H Habte; Michael W Cho; Neil S Greenspan; Thomas J Waldschmidt; Balaji Narasimhan
Journal:  J Biomed Nanotechnol       Date:  2016-06       Impact factor: 4.099

View more
  20 in total

1.  A single dose polyanhydride-based nanovaccine against paratuberculosis infection.

Authors:  Akanksha Thukral; Kathleen Ross; Chungyi Hansen; Yashdeep Phanse; Balaji Narasimhan; Howard Steinberg; Adel M Talaat
Journal:  NPJ Vaccines       Date:  2020-02-14       Impact factor: 7.344

Review 2.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

3.  Pentaerythritol-based lipid A bolsters the antitumor efficacy of a polyanhydride particle-based cancer vaccine.

Authors:  Emad I Wafa; Sean M Geary; Kathleen A Ross; Jonathan T Goodman; Balaji Narasimhan; Aliasger K Salem
Journal:  Nanomedicine       Date:  2019-07-15       Impact factor: 5.307

4.  Cationic nanoparticles enhance T cell tumor infiltration and antitumor immune responses to a melanoma vaccine.

Authors:  Rasheid Smith; Emad I Wafa; Sean M Geary; Kareem Ebeid; Suhaila O Alhaj-Suliman; Aliasger K Salem
Journal:  Sci Adv       Date:  2022-07-20       Impact factor: 14.957

Review 5.  Improving Vaccine and Immunotherapy Design Using Biomaterials.

Authors:  Michelle L Bookstaver; Shannon J Tsai; Jonathan S Bromberg; Christopher M Jewell
Journal:  Trends Immunol       Date:  2017-12-14       Impact factor: 16.687

Review 6.  Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.

Authors:  Brittany E Givens; Youssef W Naguib; Sean M Geary; Eric J Devor; Aliasger K Salem
Journal:  AAPS J       Date:  2018-10-10       Impact factor: 4.009

7.  Single Dose of a Polyanhydride Particle-Based Vaccine Generates Potent Antigen-Specific Antitumor Immune Responses.

Authors:  Emad I Wafa; Sean M Geary; Kathleen A Ross; Jonathan T Goodman; Balaji Narasimhan; Aliasger K Salem
Journal:  J Pharmacol Exp Ther       Date:  2018-10-25       Impact factor: 4.030

8.  Room Temperature Stable PspA-Based Nanovaccine Induces Protective Immunity.

Authors:  Danielle A Wagner-Muñiz; Shannon L Haughney; Sean M Kelly; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

9.  Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β.

Authors:  Luman Liu; Prakash Kshirsagar; John Christiansen; Shailendra K Gautam; Abhijit Aithal; Mansi Gulati; Sushil Kumar; Joyce C Solheim; Surinder K Batra; Maneesh Jain; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Biomed Mater Res A       Date:  2020-08-25       Impact factor: 4.396

10.  Polyanhydride Nanoparticles Induce Low Inflammatory Dendritic Cell Activation Resulting in CD8+ T Cell Memory and Delayed Tumor Progression.

Authors:  Ross Darling; Sujata Senapati; John Christiansen; Luman Liu; Amanda E Ramer-Tait; Balaji Narasimhan; Michael Wannemuehler
Journal:  Int J Nanomedicine       Date:  2020-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.